Patents by Inventor Gerald R. Crabtree
Gerald R. Crabtree has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6372712Abstract: Bifunctional molecules and methods for their use in the production of binary complexes in a host are provided. The bifunctional molecule is a conjugate of a drug moiety and a presenter protein ligand. The molecular weight of the bifunctional molecule is preferably less than about 5000 daltons, and the drug moiety may have a molecular weight of from about 50 to 2000 daltons. The drug moiety and presenter protein ligand may be covalently linked directly or through a linking group. The drug moiety binds to a drug target such as a protein and the presenter protein ligand binds to a presenter protein that is not the drug target such as extracellular or intracellular protein. Presenter proteins include peptidyl prolyl isomerase (FKBP), Heat Shock Protein 90 (Hsp90), steroid hormone receptors, cytoskeletal proteins, albumin and vitamin receptors.Type: GrantFiled: May 21, 1999Date of Patent: April 16, 2002Assignees: The Board of Trustees of the Leland Stanford Jr. University, The Howard Hughes Medical InstituteInventors: Roger Briesewitz, Gerald R. Crabtree, Thomas Wandless, Gregory Thomas Ray, Kurt William Vogel
-
Publication number: 20020042360Abstract: Methods and compositions for modulating angiogenesis in a host are provided. In the subject methods, an effective amount of Ca2+/calcineurin/NF-ATc signaling pathway modulatory agent is administered to the host. In many embodiments, the Ca2+/calcineurin/NF-ATc signaling pathway modulatory agent is an NF-ATc antagonist, e.g., in those embodiments of inhibiting angiogenesis. The subject methods find use in a variety of different applications, including the inhibition of tumor growth and the treatment of disease conditions characterized by tumor presence. Also provided are methods of screening for agents that inhibit angiogenesis by modulating the Ca2+/calcineurin/NF-ATc signaling pathway.Type: ApplicationFiled: September 19, 2001Publication date: April 11, 2002Inventors: Gerald R. Crabtree, Isabella Graef, Feng Chen
-
Patent number: 6352830Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.Type: GrantFiled: January 15, 1999Date of Patent: March 5, 2002Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Gerald R. Crabtree, Jeffrey P. Northrop, Steffan N. Ho, William M. Flanagan
-
Patent number: 6312899Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.Type: GrantFiled: June 22, 1999Date of Patent: November 6, 2001Assignee: Board of Trustees of the Leland Stanford Junior UniversityInventors: Gerald R. Crabtree, Jeffrey P. Northrop, Steffan N. Ho
-
Patent number: 6197925Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.Type: GrantFiled: June 13, 1994Date of Patent: March 6, 2001Assignee: Sara Lee CorporationInventors: Gerald R. Crabtree, Jeffrey P. Northrop, Steffan N. Ho
-
Patent number: 6171781Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.Type: GrantFiled: March 27, 1998Date of Patent: January 9, 2001Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Gerald R. Crabtree, Jeffrey P. Northrop, Steffan N. Ho
-
Patent number: 6165787Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: May 29, 1998Date of Patent: December 26, 2000Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
-
Patent number: 6150099Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.Type: GrantFiled: March 9, 1998Date of Patent: November 21, 2000Assignee: Board of Trustees of the Leland Stanford Junior UniversityInventors: Gerald R. Crabtree, Jeffrey P. Northrop, Steffan N. Ho
-
Patent number: 6140120Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .xi.Type: GrantFiled: September 16, 1998Date of Patent: October 31, 2000Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Steffan N. Ho, Peter Belshaw
-
Patent number: 6096515Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.Type: GrantFiled: March 9, 1998Date of Patent: August 1, 2000Assignee: Board of Trustees of the Leland Stanford Junior UniversityInventors: Gerald R. Crabtree, Jeffrey P. Northrop, Steffan N. Ho
-
Patent number: 6063625Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: September 16, 1998Date of Patent: May 16, 2000Assignees: Board of Trustees of Leland S, Stanford, Jr. University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Steffan N. Ho, Peter Belshaw
-
Patent number: 6054436Abstract: We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.Type: GrantFiled: May 29, 1998Date of Patent: April 25, 2000Assignees: Board of Trustees of Leland S. Stanford Jr. Univ., President & Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
-
Patent number: 6046047Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of tis invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: September 16, 1998Date of Patent: April 4, 2000Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw, Steffan N. Ho
-
Patent number: 6043082Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: September 16, 1998Date of Patent: March 28, 2000Assignees: Board of Trustees of Leland Stanford Jr. Univ., President & Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Steffan N. Ho, Peter Belshaw
-
Patent number: 6011018Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: May 29, 1998Date of Patent: January 4, 2000Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
-
Patent number: 5994313Abstract: We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.Type: GrantFiled: June 7, 1995Date of Patent: November 30, 1999Assignees: Board of Trustees of the Leland S. Stanford, Jr. Univ., President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
-
Patent number: 5989810Abstract: Activation of NF-AT-dependent transcription, including agents which interfere with the production, modification of the nuclear or cytoplasmic subunits, or the nuclear import of the cytoplasmic subunits. In particular, screening tests for novel immunosuppressants are provided based upon the ability of NF-AT to activate transcription.Type: GrantFiled: July 31, 1995Date of Patent: November 23, 1999Assignee: Board of Trustees of Leland Stanford Jr. UniversityInventors: William M. Flanagan, Gerald R. Crabtree
-
Patent number: 5871753Abstract: Methods and compositions are provided for modified cells, where a chimeric protein consisting of a ligand binding domain fused to an action domain is employed which initiates a signal which activates a biological process: transcription of at least one gene, usually a second construct introduced into the host cells; exocytosis; or an extracellular process. The second construct optimally present provides for a promoter which responds to a transcriptional activation action domain to provide for transcription, when an appropriate ligand binds to the ligand binding domain. Exemplary of the system is the use of an FKBP/CD3.zeta. or transcription factor fusion protein, using dimeric FK506 or FK520 as the ligand and a promoter responsive to NF-AT or other transcription factor requiring two molecules for transcriptional activation.Type: GrantFiled: June 7, 1995Date of Patent: February 16, 1999Assignees: Board of Trustees of the Leland Stanford Junior University, President and Fellows of Harvard CollegeInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw, Steffan Ho
-
Patent number: 5869337Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: February 14, 1995Date of Patent: February 9, 1999Assignees: President and Fellows of Harvard College, Board of Trustees of Leland S. Stanford Jr. UniversityInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
-
Patent number: 5837840Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.Type: GrantFiled: September 20, 1993Date of Patent: November 17, 1998Assignee: Board of Trustees of Leland Stanford Jr. UniversityInventors: Gerald R. Crabtree, Jeffrey P. Northrop